Migraine Treatment Switching and Costs in Medicare Patients
- 18 hours ago
- 1 min read
Research Summary
A recent study published in the Journal of Medical Economics explored treatment switching and healthcare costs among Medicare patients with chronic migraine using onabotulinumtoxinA (onabotA) or calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs). The study followed 887 patients—367 on onabotA and 520 on CGRP mAbs—over 12 months. It found that 9% of onabotA users and 18% of CGRP mAb users switched to a different migraine treatment. After adjusting for baseline differences, CGRP mAb users had 134% higher odds of switching treatments. Despite this, healthcare costs were similar between the two groups. The study highlights potential differences in treatment persistence.
Study Details
👥 Research Team: Dong Y et al.
📚 Published In: J Med Econ
📅 Publication Date: 2026 Dec
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.